Mesenchymal stem cell-based therapy in kidney transplantation.
Mesenchymal stem cell-based therapy in kidney transplantation.
复制标题
DOI：
10.1186/s13287-016-0283-6
复制
发表时间：
2016-02-07
影响因子：
7.5
通讯作者：
Hou J
中科院分区：
文献类型：
--
作者：
Chen C;Hou J
肾移植是治疗终末期肾病的最佳方法，但其实施受到器官短缺和免疫排斥反应的限制。目前免疫抑制药物的副作用，如肾毒性、机会性感染和致瘤潜力，影响长期移植结果。近年来，关于间充质干细胞（MSCs）的性质和潜在利用的持续研究和随后的发现引起了相当大的兴趣和期望。骨髓间充质干细胞具有多向分化、归巢、旁分泌和免疫调节等生物学特性，为其在肾移植中的应用开辟了新的前景。然而，许多研究表明，MSC的生物活性取决于内部炎症条件，MSC临床应用的安全性和有效性仍存在争议。本文总结了大量的研究结果，旨在提供一个客观的观点的基础上，全面分析目前建立的好处和障碍，实施MSC为基础的治疗在肾移植，并促进其临床翻译。
Kidney transplantation is the best treatment for end-stage renal disease, but its implementation is limited by organ shortage and immune rejection. Side effects of current immunosuppressive drugs, such as nephrotoxicity, opportunistic infection, and tumorigenic potential, influence long-term graft outcomes. In recent years, continued research and subsequent discoveries concerning the properties and potential utilization of mesenchymal stem cells (MSCs) have aroused considerable interest and expectations. Biological characteristics of MSCs, including multi-lineage differentiation, homing potential, paracrine effect and immunomodulation, have opened new horizons for applications in kidney transplantation. However, many studies have shown that the biological activity of MSCs depends on internal inflammatory conditions, and the safety and efficacy of the clinical application of MSCs remain controversial. This review summarizes the findings of a large number of studies and aims to provide an objective viewpoint based on a comprehensive analysis of the presently established benefits and obstacles of implementing MSC-based therapy in kidney transplantation, and to promote its clinical translation.